Media Update, page-370

I believe AT1 doesn't mention stuff when there is nothing significant to say. There is no benefit to them avoiding the much shorter India approval process for US FDA approved Covid19 tests. It would be quite silly biz wise not to be following through + against ASX disclosures rules to drop a formally ann'd expansion strategy without giving market reasons. So I am confident the CY2021 India test onboarding is still ongoing and there is nothing new to add yet.

From my tracking PoV, actually I do similar monitoring for all my portfolio stocks, for all connected partners to the respective company I am invested in, for all pipeline items in motion etc...yes, this helps me make sense of a X company's ongoing strategy of why they selected Y partner, whats going on with that related biz, potential problems or benefits downstream that might affect my invested company upstream. It makes calculating the upside/downside (rev, further expansion, changes in strategy or momentum) more easy, long term, when one is already well tuned to the distro/partner capabilities and limitations, along the way.